Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora (NASDAQ: ACB) is expanding its global medical cannabis portfolio with scaled product launches across Canada, Germany, Poland, Australia and other regulated markets between now and June.
New formats include dried flower, pre-rolls and pastilles, with cultivar-specific potencies (THC up to 29%) and multi-compound pastilles. Aurora cites its GMP-certified manufacturing network to support reliable international supply.
Aurora Cannabis (NASDAQ: ACB) acquired Safari Flower Company for aggregate consideration of $26.5 million to expand EU GMP cultivation and manufacturing capacity. The 59,000 sq ft facility will supply EU GMP flower to key markets including Germany, Australia, Poland and the UK.
The deal included issuance of 2,417,180 common shares, a $15 million cash payment on closing and a contingent $2 million cash payment. Aurora expects positive Adjusted EBITDA contributions in fiscal 2027 with additional benefits in 2028 as assets are optimized.
Aurora (NASDAQ: ACB) was named to The Globe and Mail's 2026 Report on Business Women Lead Here list for the second consecutive year on March 30, 2026. Aurora is one of 85 companies on the list and reports 50% female executive leadership.
The recognition highlights Aurora's stated commitment to inclusive executive leadership, talent development, and sustained representation; the list appears in the April 2026 issue of Report on Business magazine and online.
Aurora (NASDAQ: ACB) will participate in the TD Cowen 46th Annual Health Care Conference on March 2, 2026. CFO Simona King will join a fireside chat and investor meetings to discuss international leadership and manufacturing trends in medical cannabis.
Webcast registration is available on the company's Investor Info page and a replay will be accessible for approximately 90 days. The company also announced completion of the previously disclosed Bevo transaction dated February 4, 2026.
Aurora (NASDAQ: ACB) will ring the Nasdaq closing bell on Wednesday, February 18, 2026 at Nasdaq MarketSite in Times Square. The ceremony begins with a live broadcast at 3:45 p.m. ET and the bell will ring at 4:00 p.m. ET.
CEO and Executive Chairman Miguel Martin will lead the event alongside board and executive representatives to highlight Aurora's medical-first, global cannabis strategy and progress in international markets.
Aurora (NASDAQ: ACB) is expanding its medical cannabis portfolio in Australia and New Zealand, launching multiple THC flower products in New Zealand and four resin cartridges in Australia on Feb 11, 2026. Products use Aurora proprietary genetics and are manufactured at EU‑GMP and TGA‑GMP certified facilities in Canada.
The New Zealand roll‑out includes Big Wave, Night Ride, and Half Moon (Q1 FY27). Australia debuts Chemango Kush, Cosmic Cream, Lunar Express and Soul Train Haze, reinforcing the company’s regional growth focus.
Aurora Cannabis (NASDAQ: ACB) reported Q3 FY2026 results for the quarter ended December 31, 2025. Total net revenue rose 7% YoY to $94.2M, led by a record global medical cannabis revenue of $76.2M (+12%). Adjusted EBITDA was $18.5M, adjusted net income $7.2M, and free cash flow $15.5M. The company holds $154.4M of cash and short-term investments and says its cannabis business is debt-free aside from a $62M non-recourse Bevo Farms liability. Management reaffirmed FY2026 guidance for medical revenue of $269M–$281M and FY adjusted EBITDA of $52M–$57M.
Aurora Cannabis (NASDAQ: ACB) filed a prospectus supplement on February 4, 2026 establishing an at-the-market offering (ATM) program to issue up to U.S.$100 million of common shares from treasury. Proceeds are intended for strategic, accretive uses, including increased cultivation capacity and M&A.
Sales will occur via at-the-market distributions on NASDAQ or other U.S. marketplaces and may include privately negotiated transactions; no sales will be made on Canadian stock exchanges. The ATM is governed by a sales agreement with TD Securities (USA) LLC and the prospectus supplement and registration statement are filed in Canada (except Quebec) and with the SEC.
Aurora (NASDAQ: ACB) launched four new, localized European websites on Feb 3, 2026 to support key medical markets and a central hub at auroramedicine.com.
The sites target Germany, the UK and Poland in native languages, spotlight Canadian and local manufacturing, emphasize science-backed quality and provide resources for healthcare professionals, partners and prospective employees to strengthen regional engagement.
Aurora Cannabis (NASDAQ: ACB) will host a conference call to discuss third quarter 2026 results on Wednesday, February 4, 2026 at 8:00 a.m. Eastern Time (6:00 a.m. Mountain). The company will release Q3 2026 financial results before market open the same day.
Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, will host the call and Q&A. A live webcast link is posted under the company’s Investor Info > Events page at https://www.auroramj.com/investors/.